Sintilimab (PD-1 inhibitor)

DRUG2 trials

Sponsors

Tang-Du Hospital, Sun Yat-sen University

Conditions

Follicular Lymphoma ( FL)Large B Cell Diffuse LymphomaMantle Cell Lymphoma (MCL)Resectable Esophageal Squamous Cell Carcinoma

Phase 2

Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma

RecruitingNCT07077512

Sun Yat-sen UniversityFollicular Lymphoma ( FL), Large B Cell Diffuse Lymphoma, Mantle Cell Lymphoma (MCL)

Start: 2025-09-15End: 2027-07-15Target: 30Updated: 2026-01-21

Unknown Phase

Prospective Cohort Study of Neoadjuvant Therapy With Sintilimab (PD-1 Inhibitor) Combined With Chemotherapy in Resectable ESCC

Enrolling by invitationNCT06475196

Tang-Du HospitalResectable Esophageal Squamous Cell Carcinoma

Start: 2024-06-20End: 2025-06-20Target: 90Updated: 2024-06-26